SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFujian Cancer Hospital
About this trial
To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.
Eligibility criteria
Qualifiers
Aged 18 to 80 years, regardless of sex.
Histologically or cytologically confirmed locally advanced/metastatic renal cell carcinoma (RCC) inoperable/refused for surgery, or post-operative locally recurrent/metastatic RCC; pathological types include clear cell carcinoma and papillary renal cell carcinoma.
ECOG performance status 0 or 1.
At least 50% of all evaluable metastatic lesions are eligible for stereotactic body radiation therapy (SBRT).
Disqualifiers
With contraindications to targeted or immunotherapeutic drugs.
A history of other malignant diseases in the recent 5 years, except for cured skin cancer and carcinoma in situ of the cervix.
With active autoimmune diseases, organ transplantation, or other diseases requiring immunosuppressive therapy or long-term hormone therapy.
Extensive diffuse metastasis with an expected survival of less than 3 months.
Trial design
Treatments tested in this trial
- Stereotactic Body Radiation Therapy (SBRT)
- Anlotinib
- Bemarituzumab
Treatment groups
27 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov